1-20 of 108
Rakesh Kumar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO5-05-13: Clinical utility of whole body low dose computed tomography for detecting bone metastasis in breast cancer patients: A cross sectional study

Lipton Mitra, Suhani Suhani, Ankur Goyal, Rakesh Kumar, Mohit Joshi, Hemanga Bhattacharjee, Haresh KP, Raju Sharma, Rajinder Parshad
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-05-13.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-05-13
Published: 02 May 2024
View article titled, Abstract PO5-05-13: Clinical utility of whole body low dose computed tomography for detecting bone metastasis in breast cancer patients: A cross sectional study
Journal Articles

Abstract CT100: Safety and efficacy of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors: First-in-human study

Benedito A. Carneiro, Olumide Gbolahan, Albiruni Abdul Razak, John F. Hilton, Arthur Lambert, John Hood, Michael Pluta, Veronique Bragulat, Elhan Sanai, Rakesh Kumar, Duncan Jodrell, Patricia LoRusso
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT100.
https://doi.org/10.1158/1538-7445.AM2024-CT100
Published: 05 April 2024
View article titled, Abstract CT100: Safety and efficacy of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors: First-in-human study
Journal Articles

Abstract 7643: Prognostic significance and immune infiltration patterns related to Claudin heterogeneity in pancreatic ductal adenocarcinoma patients

Ajaz A. Bhat, Shahabuddin Usmani, Hana Q. Sadida, Sheema Hashem, Tariq Masoodi, Ikhlak Ahmed, Rakesh Kumar, Mayank Singh, Punita Dhawan, Shahab Uddin, Muzafar A. Macha, Ammira S. Al-Shabeeb Akil
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7643.
https://doi.org/10.1158/1538-7445.AM2024-7643
Published: 22 March 2024
View article titled, Abstract 7643: Prognostic significance and immune infiltration patterns related to Claudin heterogeneity in pancreatic ductal adenocarcinoma patients
Journal Articles

Abstract 2023: Multiplex immunofluorescence profiling of the tumor microenvironment and CD73: Activity of neoadjuvant oleclumab in patients with non-small-cell lung cancer in NeoCOAST

Ina Bisha, Tze Heng Tan, Manuela Weitkunat, Alma Andoni, Iris Dino, Philip Martin, Megha Saraiya, Karma DaCosta, Pallavi Sontakke, Markus Schick, Michael Surace, Jorge Blando, Italia Grenga, Rakesh Kumar, Lara McGrath
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2023.
https://doi.org/10.1158/1538-7445.AM2024-2023
Published: 22 March 2024
View article titled, Abstract 2023: Multiplex immunofluorescence profiling of the tumor microenvironment and CD73: Activity of neoadjuvant oleclumab in patients with non-small-cell lung cancer in NeoCOAST
Journal Articles

Abstract CT116: First-in-human study of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors

Benedito A. Carneiro, Maria Diab, Brian A. Van Tine, Anthony F. Shields, Albiruni Abdul Razak, John F. Hilton, Rafael Santana-Davila, Elhan Sanai, Jorge Zeron-Medina, Veronique Bragulat, Kath Lowery, Arthur Lambert, John Hood, Rakesh Kumar, Duncan Jodrell, Patricia LoRusso
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT116.
https://doi.org/10.1158/1538-7445.AM2023-CT116
Published: 14 April 2023
View article titled, Abstract CT116: First-in-human study of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors
Journal Articles

Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)

Tina Cascone, Rosario García-Campelo, Jonathan Spicer, Walter Weder, Davey Daniel, David Spigel, Maen Hussein, Julien Mazieres, Julio Oliveira, Edwin Yau, Alexander Spira, Raymond Mager, Oday Hamid, Lin-Yang Cheng, Ying Zheng, Jorge Blando, Lara McGrath, Italia Grenga, Yee Soo-Hoo, Rakesh Kumar, Patrick Forde
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT011.
https://doi.org/10.1158/1538-7445.AM2022-CT011
Published: 15 June 2022
View article titled, Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)
Journal Articles

Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC)

Tina Cascone, Alexander Spira, Rosario G. Campelo, Dong-Wan Kim, Oday Hamid, Yee Soo-Hoo, Rakesh Kumar, Italia Grenga, Patrick Forde
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT124.
https://doi.org/10.1158/1538-7445.AM2022-CT124
Published: 15 June 2022
View article titled, Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC)
Journal Articles

Abstract PD10-03: BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O)

Peter Schmid, Zbigniew Nowecki, Seock-Ah Im, Wei-Pang Chung, Simon Lord, Anne Armstrong, Cynthia X Ma, Robert Huisden, Ross Stewart, Rakesh Kumar, Gaia Schiavon, Hannah Dry, Ana Nunes, Kyung Hae Jung, Yeon Hee Park
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD10-03.
https://doi.org/10.1158/1538-7445.SABCS21-PD10-03
Published: 15 February 2022
View article titled, Abstract PD10-03: BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O)
Journal Articles

Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study

Dong-Wan Kim, Sang-We Kim, D. Ross Camidge, Naiyer A. Rizvi, Kristen A. Marrone, Xiuning Le, Collin Blakely, Keunchil Park, Gee-Chen Chang, Sandip Pravin Patel, Zachary A. Cooper, Rakesh Kumar, Ramin Samadani, Rebecca McCombs, Michael Pluta, Kevin Yufeng Wu, Suresh Ramalingam
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT163.
https://doi.org/10.1158/1538-7445.AM2021-CT163
Published: 01 July 2021
View article titled, Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study
Journal Articles

Abstract 1695: Activation of B cells by CD73 blocking antibodies

James Hair, Fabien Garcon, Michelle Hsueh, Laura Dallaway, Elena Bibikova, Maria Letizia Giardino Torchia, Gordon Moody, Alwin Schuller, Simon J. Dovedi, Zachary A. Cooper, Kris Sachsenmeier, Rakesh Kumar, Jim Eyles, Robert W. Wilkinson
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1695.
https://doi.org/10.1158/1538-7445.AM2021-1695
Published: 01 July 2021
View article titled, Abstract 1695: Activation of B cells by CD73 blocking antibodies
Journal Articles

Abstract 1828: AZD8853: A novel antibody targeting GDF15 for immunotherapy refractory tumors

Elaine Hurt, Suneetha Thomas, Kathy Mulgrew, Stephen Blackmore, James Moynihan, Fiona Cusdin, Roger Dodd, Peter Cariuk, Anna Sigurdardottir, Emily Brannigan, Claire Dobson, Rakesh Kumar, Mark Cobbold
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1828.
https://doi.org/10.1158/1538-7445.AM2021-1828
Published: 01 July 2021
View article titled, Abstract 1828: AZD8853: A novel antibody targeting GDF15 for immunotherapy refractory tumors
Journal Articles

Abstract 1584: Efficacy and pharmacodynamic effect of anti-CD73/PD-L1 monoclonal antibodies in combination with chemotherapy: Observations from mouse tumor models

Jim Eyles, Amanda Watkins, Kristina Ilieva, Stef Mullins, Jude Anderton, Elena Galvani, Fabien Garcon, Kelli Ryan, Brajesh P. Kaistha, Andreas Dannhorn, Stephanie Ling, Tim Slidel, Gozde Kar, Alwin Schuller, Zachary A. Cooper, Kris Sachsenmeier, Nadia Luheshi, Rakesh Kumar, Robert W. Wilkinson
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1584.
https://doi.org/10.1158/1538-7445.AM2021-1584
Published: 01 July 2021
View article titled, Abstract 1584: Efficacy and pharmacodynamic effect of anti-CD73/PD-L1 monoclonal antibodies in combination with chemotherapy: Observations from mouse tumor models
Journal Articles

Mesenchymal Stem Cell–Secreted Extracellular Vesicles Instruct Stepwise Dedifferentiation of Breast Cancer Cells into Dormancy at the Bone Marrow Perivascular Region

Oleta A. Sandiford, Robert J. Donnelly, Markos H. El-Far, Lisa M. Burgmeyer, Garima Sinha, Sri Harika Pamarthi, Lauren S. Sherman, Alejandra I. Ferrer, Dariana E. DeVore, Shyam A. Patel, Yahaira Naaldijk, Sara Alonso, Pradeep Barak, Margarette Bryan, Nicholas M. Ponzio, Ramaswamy Narayanan, Jean-Pierre Etchegaray, Rakesh Kumar, Pranela Rameshwar
Journal: Cancer Research
Cancer Res (2021) 81 (6): 1567–1582.
https://doi.org/10.1158/0008-5472.CAN-20-2434
Published: 15 March 2021
View article titled, Mesenchymal Stem Cell–Secreted Extracellular Vesicles Instruct Stepwise Dedifferentiation of Breast Cancer Cells into Dormancy at the Bone Marrow Perivascular Region
Open the PDF for Mesenchymal Stem Cell–Secreted Extracellular Vesicles Instruct Stepwise Dedifferentiation of Breast Cancer Cells into Dormancy at the Bone Marrow Perivascular Region in another window
Includes: Supplementary data
Journal Articles

Abstract 6325: CXCR4 intracellular protein regulates chemotherapy resistance by modulating the expression of death receptor 5

Mushtaq Ahmad Nengroo, Shrankhla Maheshwari, Akhilesh Singh, Anup Kumar Singh, Priyank Chaturvedi, Ayushi Verma, Rakesh Kumar Arya, Krishan Kumar Saini, Annapurna Gupta, Anjali Mishra, Dipak Datta
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6325.
https://doi.org/10.1158/1538-7445.AM2020-6325
Published: 15 August 2020
View article titled, Abstract 6325: CXCR4 intracellular protein regulates chemotherapy resistance by modulating the expression of death receptor 5
Journal Articles

A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy

Rakesh Kumar, Marc Van de Vijver, Giampaolo Tortora, Fortunato Ciardiello, Tzipora Goldkorn, Wilson H. Miller, Jr, Larry Norton
Journal: Cancer Research
Cancer Res (2019) 79 (17): 4315–4323.
https://doi.org/10.1158/0008-5472.CAN-19-0989
Published: 03 September 2019
View article titled, A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy
Open the PDF for A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy in another window
Journal Articles

Abstract 3021: Plexin-B3 regulates cellular motility, invasiveness and metastasis in pancreatic cancer

Sugandha Saxena, Yuri Hayashi, Satyanarayana Rachagani, Surinder Kumar Batra, Rakesh Kumar Singh
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3021.
https://doi.org/10.1158/1538-7445.AM2018-3021
Published: 01 July 2018
View article titled, Abstract 3021: Plexin-B3 regulates cellular motility, invasiveness and metastasis in pancreatic cancer
Journal Articles

Abstract 711: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Stefanie R. Mullins, John Vasilakos, Katharina Deschler, Iwen Grigsby, Song Ren, Matthew J. Elder, Simon J. Dovedi, Andrew J. Leishman, Patricia Ryan, Zachary Cooper, James Elvecrog, Ronald Herbst, Rakesh Kumar, Mark Tomai, Robert W. Wilkinson
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 711.
https://doi.org/10.1158/1538-7445.AM2018-711
Published: 01 July 2018
View article titled, Abstract 711: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
Journal Articles

Abstract 2919: Discovery of small-molecule compounds targeting c-MYC using a novel cell-based screen

Biju Mangatt, Anthony D. Pietra, Anna Waszkiewicz, Jon-Paul Jaworski, Sonja Ghidelli-Disse, Thomas J. Berrodin, Christian S. Sherk, Derrick W. Meinhold, Anna Rutkowska-Klute, Shanker K. Sundaram, Gopinath Ganji, Wendy S. Halsey, George P. Livi, William Li, James Mack, Stuart P. Romeril, Elisabeth A. Minthorn, Rakesh Kumar, Gerard C. Drewes, Dirk A. Heerding, Lorena A. Kallal, Carolyn A. Buser, Jesus R. Medina
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2919.
https://doi.org/10.1158/1538-7445.AM2018-2919
Published: 01 July 2018
View article titled, Abstract 2919: Discovery of small-molecule compounds targeting c-MYC using a novel cell-based screen
Journal Articles

Abstract 5604: Novel biomarkers Ly6E/K play important role in drug resistance and tumor immune escape

Midar A. Hossiny, William R. Frazier, Noriko Steiner, Bhaskar Kallakury, Rakesh Kumar, Geeta Upadhyay
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5604.
https://doi.org/10.1158/1538-7445.AM2017-5604
Published: 01 July 2017
View article titled, Abstract 5604: Novel biomarkers Ly6E/K play important role in drug resistance and tumor immune escape
Journal Articles

Abstract 4697: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors

Stefanie R. Mullins, Katharina Vogel, John Vasilakos, Iwen Grigsby, Simon Dovedi, Ryan Patricia, Zachary Cooper, Ronald Herbst, Rakesh Kumar, Mark Tomai, Robert W. Wilkinson
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4697.
https://doi.org/10.1158/1538-7445.AM2017-4697
Published: 01 July 2017
View article titled, Abstract 4697: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors